Head to Head Survey: iRadimed (NASDAQ:IRMD) & Pressure BioSciences (OTCMKTS:PBIO)

Pressure BioSciences (OTCMKTS:PBIO) and iRadimed (NASDAQ:IRMD) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends and valuation.

Institutional and Insider Ownership

0.0% of Pressure BioSciences shares are owned by institutional investors. Comparatively, 92.3% of iRadimed shares are owned by institutional investors. 10.8% of Pressure BioSciences shares are owned by insiders. Comparatively, 36.8% of iRadimed shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Pressure BioSciences and iRadimed”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pressure BioSciences	$1.98 million	0.02	-$29.31 million	($0.96)	0.00
iRadimed	$80.51 million	14.55	$19.23 million	$1.65	55.79

iRadimed has higher revenue and earnings than Pressure BioSciences. Pressure BioSciences is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Pressure BioSciences and iRadimed, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pressure BioSciences	0	0	0	0	0.00
iRadimed	0	1	4	0	2.80

iRadimed has a consensus target price of $87.33, suggesting a potential downside of 5.13%. Given iRadimed’s stronger consensus rating and higher possible upside, analysts clearly believe iRadimed is more favorable than Pressure BioSciences.

Profitability

This table compares Pressure BioSciences and iRadimed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pressure BioSciences	N/A	N/A	N/A
iRadimed	26.61%	23.30%	20.62%

Risk & Volatility

Pressure BioSciences has a beta of -0.2, meaning that its stock price is 120% less volatile than the S&P 500. Comparatively, iRadimed has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500.

Summary

iRadimed beats Pressure BioSciences on 14 of the 14 factors compared between the two stocks.

About Pressure BioSciences

Pressure BioSciences, Inc. develops and sells pressure-based platform solutions in the North America, Europe, and Asia. The company's pressure cycling technology (PCT) technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, including cells and tissues from human, animal, plant, and microbial sources. It offers Barocycler instrumentations comprising Barocycler 2320EXT, Barocycler HUB880, Barocycler HUB440, and the Shredder SG3. The company also distributes cell disruption equipment, parts, and consumables. In addition, it offers Barocycler consumable products, such as PCT MicroTubes, PCT MicroCaps, PCT-Micro Pestle, and pressure used to lyse samples for extraction tubes, as well as application specific kits, including consumable products and reagents. The company serves researchers at academic laboratories, government agencies, biotechnology companies, pharmaceutical firms, and other life science institutions. It has collaborations with RedShiftBio Inc.; Inova Schar Cancer Center; NYU; Leica Microsystems, GmbH; Steinbeis Centre for biopolymer analysis and biological mass spectrometry; The Ohio State University; University of Delaware; and Cedars Sinai Medical Center. The company was formerly known as Boston Biomedica, Inc. and changed its name to Pressure BioSciences, Inc. in September 2014. The company was incorporated in 1978 and is based in South Easton, Massachusetts.

About iRadimed

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.